<DOC>
	<DOCNO>NCT01660360</DOCNO>
	<brief_summary>The primary objective study ass safety , tolerability , maximum tolerate dose ( MTD ) Tanibirumab patient advance metastatic cancer refractory standard therapeutic option . - To evaluate pharmacokinetics Tanibirumab patient - To determine recommended phase II dose ( RP2D ) Tanibirumab base assessment</brief_summary>
	<brief_title>Phase I Trial Tanibirumab Advanced Metastatic Cancer</brief_title>
	<detailed_description>This Phase I , first-in-human , open-label , non-randomized , dose-escalating study Tanibirumab fully human monoclonal antibody vascular endothelial growth factor receptor 2 ( VEGFR2/KDR ) . This study enroll patient advance metastatic cancer refractory standard therapeutic option . Tanibirumab administer intravenously patient 60 minute Day 1 , 8 , 15 ( subject change pending PK toxicity data ) . Each treatment cycle minimum 28 day length . The dose escalation study employ 3 + 3 design design identify RP2D base safety , tolerability PK RP2D . This study expect enroll total approximately 18-24 patient .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Age &gt; 20 year Signed informed consent Histologically document , incurable , locally advanced metastatic cancer fail respond least one prior regimen standard therapy . Disease measurable evaluable RECIST 1.1 criterion ( Solid Tumors ) ECOG performance status 02 Documented negative pregnancy test woman childbearing potential use effective mean contraception men woman enrol study Granulocyte count ≥ 1,500/㎣ , platelet count ≥ 100,000/㎣ , hemoglobin ≥ 9 g/dL Serum bilirubin ≤ 1.5 x upper limit normal ( ULN ) ( ≤ 3 x ULN liver metastatic cancer ) Alkline phosphatase , AST ALT ≤ 2.5 x ULN ( ≤ 5 x ULN liver metastatic cancer ) Serum creatinine ≤ 1.5 mg/dL INR ( international normalize ratio ) ≤ 1.3 , aPTT ( activate partial thromboplastin time ) ≤ 1.5 x ULN Subject project life expectancy least 3 month Bazetts correction QTc &lt; 450 msec ECG Screening Less 4 week since last chemotherapy ( include biologic unless previous Avastin treatment , experimental , hormonal therapy ) , radiation therapy , major surgical procedure All incision procedure must fully heal suture remove prior infusion Day 1 Pleural effusion , ascites , leptomeningeal disease manifestation current malignancy Subjects hypertension remain uncontrolled , despite drug regimen . Subjects grade III IV hemorrhage/bleeding experienced pulmonary hemorrhage/hemoptysis ( exceed size 2.5 mL erythrocyte ) experience grade III/IV hemorrhage/bleeding . The presence gastrointestinal perforation The presence tracheoesophageal fistula grade Ⅳ fistula Subjects grade Ⅳ proteinuria ( nephritic syndrome ) The presence arterial thromboembolic event Subjects history life threatening ( grade Ⅳ ) pulmonary embolism Subjects know hypersensitivity CHO cell product recombine human humanize antibody Subjects mental illness Subjects know hypersensitivity ingredients/substrates investigational product study Subjects give investigational drug within long period 30 day 5 time half life participation study Active infection require IV antibiotic Active autoimmune disease control drug Clinically important history liver disease , include viral active hepatitis , current alcohol abuse , cirrhosis Known human immunodeficiency virus ( HIV ) infection Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render subject high risk treatment complication Significant traumatic injury within 3 week Day 1 Inability comply study followup procedure</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Tanibirumab Phase I trial</keyword>
</DOC>